Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 6/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 8/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644880 | 1.00 | CSNK1E (0.42) | CSNK1EEGFRBTKCSNK1DKDM1A | |
| SCHEMBL26644829 | 0.89 | BTK (0.40) | CSNK1EEGFRBTKCSNK1DTXK | |
| SCHEMBL30622358 | 0.89 | BTK (0.40) | CSNK1EEGFRBTKCSNK1DTXK | |
| SCHEMBL26645610 | 0.87 | BTK (0.39) | CSNK1EEGFRBTKCSNK1DKDM1A | |
| SCHEMBL26644936 | 0.86 | CSNK1E (0.41) | CSNK1EBTKCSNK1DPDE4APDE4B | |
| SCHEMBL30622850 | 0.86 | CSNK1E (0.42) | CSNK1ECSNK1DKDM1APDE4APDE4B | |
| SCHEMBL26645016 | 0.86 | CSNK1E (0.42) | CSNK1ECSNK1DKDM1APDE4APDE4B | |
| SCHEMBL30622390 | 0.85 | CSNK1E (0.41) | CSNK1EEGFRBTK | |
| SCHEMBL26644886 | 0.85 | CSNK1E (0.41) | CSNK1EEGFRBTK | |
| SCHEMBL26644827 | 0.85 | CSNK1D (0.43) | CSNK1EBTKCSNK1DFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |